Cryoalfa Europe Ltd

Cryosurgery for a Natural Healing Process Without Notable Side-effects

Our cryosurgical device CRYOALFA fits into any pocket and is always ready to hand for removal of all every-day-skin lesions such as all kind of warts, keratosis, fibromas, pigmentary disorders, precancerous lesions and many more. In the urogynecology are treated such as cervical changes, condylomas, in the biological dentistry the gums are treated. Any special applicators are also available for a wide variety of applications.The impact of cold by our leight-weigth especially easily-handled doser (by one hand and one finger) is precise to the lesion that to be treated. Within 12s the treated skin area is frozen in a diameter about 10mm up to an internal skin depth of 3mm. A safe cell's death unwanted cells (benigne or maligne cells) will be guaranteed in the lowest skin layer. The treatment takes only just a few seconds depending on the skin lesion. A scab (necrosis) will form after 2-3 days after the treatment. After further 10-14 days the scrab will drop off. The treated skin will return to normality within 3-4 weeks with good cosmetic effects.

We are the Original,we are the innovators of this extremely efficient cryo-system called "Liquid freezing". Our Original "Liquid freezing" -system is characterised  by connection small cartridges onto the refrigerant metering unit. Our cartridges are available in the sizes of 8g,12g,16g and 25g filled with pure medically liquid N2O gas manufactured by LINDE.CRYOALFA is the first small mobile device with operating parameters achieving therapy results about 94% percent success rate. Besides the many offered confusing cryo-products now, only 3 groups of refrigerants are still important: CO2 (temperature of -78°C/-108°C) for non neoplastics lesions, N2O (temperature of -89°C/ -128°F) as "Liquid freezing" such as in closed probes (N2O flows through the closed probe) for superficial lesions, and especially because of the lower cryogenic stick-effect to the oral and genital surfaces compared to N2 (nitrogen) and N2 (-196°C/ -320°F) for tumours (Akt.Dermatol 2009;35;279-282).

Our "Liquid-freezing"- system is registered in patent offices under: Japan Patent 4 605 809, China Patent ZE 00134458.7, Canada Patent 2,571,006, US Patent 8,083,734 B2, Hong Kong Patent HK 10386886